In an 87-year-old female with major depressive disorder, Alzheimer’s disease with mild dementia and behavioral disturbances (agitation, anxiety, insomnia, wandering, restlessness) currently prescribed sertraline, brexpiprazole, quetiapine, divalproex sodium, trazodone, and melatonin, who is experiencing increased agitation, medication refusal, and difficulty being redirected, what additional assessments or non‑pharmacologic strategies should be considered?

Prioritize Non-Pharmacologic Interventions and Systematic Medical Assessment

You are missing a comprehensive medical workup for reversible causes of agitation and a structured non-pharmacologic approach—this patient's medication burden is excessive and may be contributing to her worsening agitation, medication refusal, and behavioral decline.

Immediate Assessment Priorities

Rule Out Medical Causes of Acute Agitation

Before adding or adjusting medications, systematically evaluate:

• Pain assessment: Use observational pain scales (PAINAD, PACSLAC) since she cannot reliably self-report. Unrecognized pain is a leading cause of agitation in dementia 1
• Infection workup: Urinary tract infection, pneumonia, or other occult infections commonly trigger acute behavioral changes
• Constipation/urinary retention: Perform abdominal exam and bladder scan
• Medication side effects: Her current regimen includes multiple sedating agents that may cause paradoxical agitation, oversedation leading to confusion, or anticholinergic burden
• Dehydration/electrolyte disturbances: Check basic metabolic panel, especially given vitamin D deficiency
• Environmental triggers: Assess for overstimulation, understimulation, unmet needs (hunger, thirst, toileting)

Critical Medication Review

Your patient is on a dangerously high medication burden that likely worsens her condition. She is receiving:

• Two antipsychotics (brexpiprazole 3 mg + quetiapine 25 mg)
• One mood stabilizer (divalproex)
• Two sedating agents (trazodone + melatonin)
• One antidepressant (sertraline)

This polypharmacy increases fall risk, cognitive impairment, and paradoxical agitation 2. The 2025 geriatric emergency guidelines found that adverse drug events occurred in 16.8% of older adults receiving antipsychotic or anxiolytic medications, with oral medications (particularly quetiapine) having the best safety profile 2.

Non-Pharmacologic Strategies (First-Line Treatment)

Non-pharmacologic approaches are recommended as preferred first-line treatment for agitation in dementia except in emergency situations 1. Implement these systematically:

Structured Environmental Modifications

• Reduce stimulation: Minimize noise, bright lights, and multiple simultaneous activities
• Establish predictable routines: Same caregivers, same times for meals/activities/sleep
• Create safe wandering spaces: Since she has documented wandering behavior
• Optimize lighting: Increase daytime light exposure to help normalize circadian rhythms 3

Person-Centered Communication Approaches

• Validation therapy: Acknowledge her feelings without arguing or correcting
• Redirect rather than confront: When she refuses medications, don't force—return later with different approach
• Simplify communication: One-step instructions, calm tone, maintain eye contact
• Identify behavioral triggers: Keep a log of when agitation occurs and what precedes it

Activity-Based Interventions

• Structured daily activities: Music therapy, simple crafts, folding tasks
• Increased physical activity: Walking programs improve both agitation and sleep 4
• Social engagement: Even brief interactions reduce isolation-related agitation 4

Medication Optimization Strategy

Step 1: Simplify the Regimen

Consider tapering/discontinuing medications rather than adding more:

1. Quetiapine 25 mg: This dose is subtherapeutic for agitation (guidelines recommend starting 12.5 mg BID, titrating to 200 mg BID for effect) 5. Either increase to therapeutic dose OR discontinue since brexpiprazole is already prescribed for agitation

2. Divalproex sodium: You're already tapering this appropriately. Continue the taper as planned since divalproex requires monitoring and has problematic side effects 5

3. Sertraline 25 mg: This is a low dose. Antidepressants in Alzheimer's disease show modest and inconsistent benefits with risks including falls, hyponatremia, and possible cognitive decline acceleration 6. If depression is not clearly functionally impairing, consider tapering after 9 months per guidelines 5

Step 2: Optimize Brexpiprazole Use

Brexpiprazole 3 mg is FDA-approved for agitation in Alzheimer's disease 7, 8, 9. However:

• It takes 6-12 weeks to separate from placebo 10
• Effect sizes are small 10
• It works best for severe agitation/aggression 8, 10
• Black box warning: Increased mortality risk in elderly patients with dementia-related psychosis 7

If she's been on brexpiprazole less than 12 weeks, continue it. If longer without benefit, question whether it's helping.

Step 3: Address Sleep Without Polypharmacy

Her insomnia regimen (trazodone 50 mg + melatonin 3 mg + quetiapine 25 mg) is excessive:

• Trazodone: Guidelines support 25-400 mg for agitation/sleep 5. Her 50 mg dose is reasonable
• Melatonin: Can continue as low-risk option
• Quetiapine 25 mg QHS: Redundant with trazodone; discontinue or increase to therapeutic dose

Sleep hygiene is critical: Reduce daytime napping, increase daytime light exposure and physical activity, establish consistent bedtime routine 3.

What You're Actually Missing

1. Medication Administration Technique

She's spitting out medications—this suggests:

• Pills may be too large or unpleasant
• She may have dysphagia (evaluate swallowing)
• Timing may be poor (trying during agitated state)
• Solution: Consider liquid formulations, crush medications if appropriate (check with pharmacy—some cannot be crushed), administer during calm periods, hide in preferred foods if ethically acceptable

2. Caregiver Assessment and Support

Caregiver distress directly impacts patient agitation 1. Assess:

• Caregiver depression, burnout, and stress levels
• Caregiver understanding of dementia behaviors
• Caregiver training in de-escalation techniques
• Need for respite care or additional support

3. Functional Assessment

Evaluate:

• Activities of daily living (ADLs) and instrumental ADLs
• Mobility and fall risk (she's on multiple sedating medications)
• Nutritional status (weight loss common with agitation)
• Hearing and vision (sensory impairment worsens agitation)

4. Psychiatric Consultation

Given complex medication regimen and refractory symptoms, consider geriatric psychiatry referral for:

• Medication optimization
• Differential diagnosis (is this agitation, akathisia from medications, or undertreated depression?)
• Consideration of alternative agents if current regimen fails

Specific Algorithm for This Patient

Week 1-2:

1. Complete medical workup (labs, infection screen, pain assessment)
2. Implement non-pharmacologic interventions (environmental modifications, structured activities)
3. Begin quetiapine taper (discontinue since dose is subtherapeutic and brexpiprazole is prescribed)
4. Address medication administration barriers (liquid formulations, timing)

Week 3-4:

1. If agitation improves: Continue current approach, monitor closely
2. If agitation persists: Evaluate brexpiprazole duration—if <12 weeks, continue; if >12 weeks without benefit, consider taper
3. Reassess need for sertraline if depression not functionally impairing

Week 5-8:

1. If agitation worsens: Consider increasing trazodone (up to 200-400 mg in divided doses) as mood-stabilizing alternative 5
2. Avoid benzodiazepines—they cause paradoxical agitation in 10% of dementia patients and increase fall/cognitive impairment risk 5
3. Consider geriatric psychiatry referral if no improvement

Critical Safety Considerations

Avoid these common pitfalls:

• Do not add benzodiazepines: High risk of adverse events, especially midazolam 2
• Do not use typical antipsychotics: 50% risk of tardive dyskinesia after 2 years in elderly 5
• Monitor for extrapyramidal symptoms: Brexpiprazole can cause these 7
• Watch for falls: Multiple sedating medications dramatically increase risk
• Screen for hyponatremia: Sertraline risk, especially in elderly 11

The most important intervention is stepping back from reflexive medication escalation and implementing systematic medical assessment plus evidence-based non-pharmacologic strategies 2, 1.